JCR Pharmaceuticals achieved sales of 9.7 billion yen (up 13.2% YoY) in the first quarter of fiscal 2027, but recorded losses in operating, ordinary, and net income. Increased research and development expenses and progress in new drug development are expected to drive future growth.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4552","jir_company_name":"JCR Pharmaceuticals Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-07-30","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/07\/4552-20260730-02.pdf","jir_short_summary":"JCR Pharmaceuticals achieved sales of 9.7 billion yen (up 13.2% YoY) in the first quarter of fiscal 2027, but recorded losses in operating, ordinary, and net income. Increased research and development expenses and progress in new drug development are expected to drive future growth.","jir_summary":"### Financial Results Overview\nJCR Pharmaceuticals recorded net sales of 9.7 billion yen (up 13.2% YoY) in the first quarter of fiscal 2027, but reported an operating loss of 2.13 billion yen, an ordinary loss of 2.084 billion yen, and a net loss of 1.97 billion yen. R&D expenses increased by 75.9%, focusing on clinical trial progress and new drug development. The sales increase was driven by strong performance of mucopolysaccharide therapy, with further R&D progress expected to be key for reversing performance.\n\n### Outlook and Investment Considerations\nThe company maintains its earnings forecast for this period, with projected net sales of 45.7 billion yen. However, ongoing increases in R&D investment may lead to continued losses. Progress in clinical trials and R&D expenses are expected to support long-term growth, though short-term losses are likely to persist. The company's assets and liabilities remain stable, and initiatives to strengthen capital policies and expand research bases are ongoing.","jir_financial_highlights":"Net sales: 9.7 billion yen (Up 13.2% YoY)\nOperating income: \u25b32.13 billion yen (Loss expanded compared to the same period last year)\nNet income attributable to owners of parent: \u25b31.97 billion yen (Loss expanded compared to the same period last year)","jir_category":"","jir_hashtags":"#JCRPharmaceutical, #FinancialResults, #JapaneseStocks","jir_key_figures":"Net sales: 9.7 billion yen (up 13.2% YoY)\nNet income attributable to owners of parent: 1.97 billion yen\nResearch and development expenses: 5.888 billion yen (up 75.9% YoY)","jir_meta_title":"\u3010JCR Pharmaceuticals\u30112027 Q1 Results\uff5cSales of 9.7 billion yen (+13.2%)","jir_meta_description":"JCR Pharmaceuticals achieved sales of 9.7 billion yen in the first quarter of fiscal 2027, but losses widened. Progress in R&D and new drug clinical trials are expected to drive future growth.","jir_og_title":"\u3010JCR Pharmaceuticals\u30112027 Q1 Results\uff5cSales of 9.7 billion yen ( +13.2%)","jir_og_description":"JCR Pharmaceuticals\u2019 Q1 2027 results show sales of 9.7 billion yen and widening losses, but advancements in R&D are promising. A valuable reference for long-term growth investment decisions.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":9680,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-90547","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n